A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
ConditionNon-Small-Cell Lung
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAstraZeneca
About this trial
This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Stage I-III at initial NSCLC diagnosis
Aged ≥18 years at first diagnosis of NSCLC
Disqualifiers
NSCLC is not the primary cancer diagnosis
Patients with a recent history of other tumor or concurrent other tumor
Patients participating in interventional clinical trials at time of initial diagnosis
Patients with positive pregnancy status at the time of diagnosis
Trial population
The target population for this study will be patients diagnosed with stage I-III NSCLC treated in routine clinical practice with various treatment regimens (e.g., definitive treatment with surgery or radiotherapy, neoadjuvant, adjuvant and perioperative systemic therapies) who meet the study eligibility criteria.
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Treatment Patterns
Proportion of patients with different treatment regimens
Time frame
Up to 50 months2
Proportion of unresected patients in SI/II/III
Proportion of patients who are unresected among SI/II/III NSCLC patients enrolled, respectively
Time frame
Up to 50 months3
CRT rate in USIII
Proportion of patients who have CRT regimen among unresected SIII patients enrolled
Time frame
Up to 50 monthsSecondary outcomes
1
Treatment Duration
TKI treatment duration and discontinuation reason in EGFRm patients * Duration of treatment * Treatment discontinuation (time to discontinuation, and reason for discontinuation)
Time frame
Up to 50 months2
Patterns of recurrence
Type of recurrence following initial treatment regimen (Loco-regional recurrence, distant recurrence, other)
Time frame
Up to 50 months3
Guideline adoption rate
Resected EGFRm Stage IB-III * Proportion of patients received guideline recommended TKI adjuvant regimen among a. resected EGFRm Stage IB-III patients; b. patients with TKI adjuvant therapy Unresected Stage III * Proportion of patients received guideline recommended systemic IO and TKI regimens among patients who received CRT
Time frame
Up to 50 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov